A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.

José Germán Sánchez-Hernández Noemi Rebollo Ana Martin-Suarez María Victoria Calvo Fernando Muñoz

Published in: British journal of clinical pharmacology (2020)

This study found that compared to empirical dosing, mep-TDM is associated with improved efficacy and safety of infliximab therapy, reduced IBD-related hospitalization and surgery and incidence of SIRs, and increasing long-term durability of treatment effects.

Keyphrases

ulcerative colitis
minimally invasive
coronary artery bypass
risk factors
study protocol
randomized controlled trial
stem cells
quality improvement